Summarized by Masters of Longevity from Longevity Technology.
WVE-007 markedly reduced circulating INHBE protein in early clinical updates.

Key Takeaways
- WVE-007 is a GalNAc-siRNA targeting INHBE in humans.
- Treatment produced reductions in circulating INHBE protein up to 88%.
- Presented data were clinical updates, not pivotal trial results.



